Time trend of cardiometabolic risk factors over a 10-year period in the office-working population in China

Yang Cheng,1 Hongli Yin,1 Hui Zheng,1 Donghua Yin,1 Gang Yin,1 Shanping Ying,1 Xiaohong Li,1 Hui Dai,1 Lvkun Zhao,1 Chong Shen,2,3 Zhixiang Shen,1 Liubao Gu2

ABSTRACT

Objectives Recent dramatic increases in cardiovascular disease mortality in China can be mostly explained by adverse changes in hypertension, dyslipidaemia, diabetes and obesity, known as cardiometabolic risk factors. Our study aimed to assess the trend of these four signatures by a 10-year lag in Nanjing, China.

Methods 8017 subjects attended the routine health examination in 2008, and 9379 subjects in 2017, from multiple work units of Nanjing, were included in the present study. The prevalence and trend of four cardiometabolic risk factors: hypertension, dyslipidaemia, diabetes and obesity were analysed.

Results From 2008 to 2017, the prevalence of hypertension declined, while the prevalence of dyslipidaemia, diabetes and obesity increased. Besides, the population in 2008 and 2017 had an average of 0.66 and 0.78 risk factors, respectively.

Conclusion Cardiometabolic risk factors are common for the staff in administrative agencies and institutions of Nanjing, China. Effective screening and interventions against these risk factors should be adopted in high-risk populations such as the office-working population in China.

INTRODUCTION

Cardiovascular disease (CVD) is highly prevalent and remains the predominant cause of premature mortality worldwide.1 In China, the estimated annual deaths due to CVD increased to 2.7 million, which accounts for about 40% of all-cause mortality per year.2 Obesity, diabetes, hypertension and dyslipidaemia are established risk factors of CVD and contribute to the prevalence of CVD,3–8 which were also known as cardiometabolic risk factors because of their close link with metabolic disorders, cancers and chronic respiratory diseases.9 10

In recent years, a substantial increase was seen in the prevalence of overweight and diabetes mellitus worldwide,11 12 whereas the prevalence of hypertension was reported to be stable over time13–15 and the prevalence of hypercholesterolaemia remained at almost epidemic levels.16–18 In China, with the huge economic development and changes in lifestyles including higher calorie and cholesterol intake and reduced physical activity, the frequencies and profiles of four signatures such as obesity, diabetes, hypertension and dyslipidaemia have changed even more dramatically. Given the ongoing deterioration of these cardiometabolic risk factors in China, which may greatly contribute to the surge of cardiometabolic health, more understanding of these factors may be quite important. However, to date, little is known about the time trend of these risk factors in China.

The present study aims to investigate the long-term trends of cardiometabolic risk factors in the office-working population in China by a 10-year lag from 2008 and 2017, using a large health administrative database in Jiangsu, China. The office-working population has been shown to be ‘high risk group’ for metabolic diseases19 due to their lifestyle, as most of them perform their daily work mainly in the office with low amount of physical activity.

METHODS

Participants This was an observational study using health check-up data from the health management centre in the Geriatric Hospital of Nanjing
Medical University (Nanjing, China). Subjects included in the study came from dozens of work units including government offices, scientific research institutions, banks and so on, in the major urban districts of Nanjing, which is the capital of Jiangsu Province located in the east of China. Most of them perform their daily work mainly in the office with low amounts of physical activity. We also included both currently employed and retired individuals in our study. Totally, 9665 subjects in 2008 and 15200 subjects in 2017 undergoing a routine annual health check-up in the health management centre were included; the health check-up included a medical examination, anthropometric measurements and information on medical history. There was no difference in the design and recruitment between 2008 and 2017.

After excluding those participants with missing data on height (n=450), systolic pressure (n=29), low-density lipoprotein cholesterol (LDL-C) (n=938) or information of prior history of hypertension, dyslipidaemia and diabetes (n=231), 8017 individuals were eligible for analysis at baseline in 2008. Similarly, a population of 9379 individuals remained for analysis in 2017 after excluding those under 18 years of age (n=21), or those with missing data on height (n=1476), systolic pressure (n=128), blood glucose (n=312), LDL-C (n=3001) or information of prior history of hypertension, dyslipidaemia and diabetes (n=883). Written informed consent was obtained from all participants.

**Clinical assessment**

Demographic characteristics including age and sex were collected from all participants. Personal medical history, including hypertension, diabetes and dyslipidaemia, was reported by all participants. Body weight, height and blood pressure were measured using standard instruments and protocols by trained nurses.20 Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. LDL-C and fasting plasma glucose (FPG) were measured during an overnight fast of more than 11 hours. We defined the same four signatures for cardiometabolic risk factors in 2008 and 2017 (also see online supplementary table 1): (1) Obesity: BMI≥28 kg/m.21–23 (2) Hypertension: blood pressure ≥140/90 mm Hg and/or self-reported history of hypertension.24 (3) Dyslipidaemia: LDL-C ≥4.14 mmol/L and/or self-reported dyslipidaemia.25 (4) Diabetes: FPG≥7.0 mmol/L and/or self-reported diabetes.26

**Statistical analysis**

Comparisons between different years were conducted using Student’s test for continuous variables and χ² test for categorical variables. Comparison between prevalence data of 2008 and 2017 was performed on the basis of standardised mortality rate calculations and by applying the indirect standardisation technique, using reference-specific prevalence rates of hypertension, dyslipidaemia and diabetes by age and gender using the population composition from the Chinese census population (aged 19–96 years).27 Data analyses were carried out by R software (V.3.0.2, 2013-09-25; R Foundation for Statistical Computing, http://www.cran.r-project.org/). The significance level was set at p<0.05 and p values were given for two-sided tests.

**Patient and public involvement**

The participants of this study represent a large office-working population in China. They were not involved either in the study design, nor in the conduct of the study. However, they were informed that their physical examination data (including blood pressure, cholesterol levels, blood glucose, etc) and baseline information may be used in a scientific study. All scientific study results were continuously communicated to the participants by phone.

**RESULTS**

The characteristics of the study population are shown in online supplementary table 2. A total of 8017 and 9397 subjects were included in the analysis in 2008 and 2017, respectively. There was no statistically significant difference in sex distribution. Compared with those of 2008, the percentages of older (age ≥60 years), overweight

---

**Open access**

### Table 1  The prevalence rates of hypertension, dyslipidaemia, diabetes and obesity in 2008 and 2017 based on examination tests and self-reports

| Disease       | Survey year | No. of subjects | No. of cases | Prevalence (95% CI) (%) | Standard prevalence (95% CI) (%) | P values † |
|---------------|-------------|-----------------|--------------|-------------------------|----------------------------------|------------|
| Hypertension  | 2008        | 8017            | 3036         | 37.87 (36.81 to 38.93)  | 27.51 (26.53 to 28.49)          | <0.001     |
|               | 2017        | 9379            | 3671         | 39.14 (38.15 to 40.13)  | 25.16 (24.28 to 26.04)          |            |
| Dyslipidaemia | 2008        | 8017            | 869          | 10.84 (10.16 to 11.52)  | 8.25 (7.65 to 8.85)             | <0.001     |
|               | 2017        | 9379            | 1332         | 14.20 (13.49 to 14.91)  | 11.95 (11.29 to 12.61)          |            |
| Diabetes      | 2008        | 8017            | 687          | 8.57 (7.96 to 9.18)     | 5.40 (4.91 to 5.89)             | <0.001     |
|               | 2017        | 9379            | 1141         | 12.17 (11.51 to 12.83)  | 6.68 (6.17 to 7.19)             |            |
| Obesity       | 2008        | 8017            | 725          | 9.04 (8.41 to 9.67)     | 7.44 (6.87 to 8.01)             | <0.001     |
|               | 2017        | 9379            | 1154         | 12.30 (11.64 to 12.96)  | 11.33 (10.69 to 11.97)          |            |

*Standardised prevalence; the prevalence rates were standardised by age and sex based on the 2010 Chinese census population.

†P values for standardised prevalence between 2008 and 2017.
and obese subjects increased by 9.89%, 2.42% and 3.26%, respectively in 2017. In addition, in 2017, more subjects had a history of the three medical conditions (systolic blood pressure, LDL-C and blood glucose).

The crude prevalence of hypertension, dyslipidaemia, diabetes and obesity increased over the study period, from 37.87%, 10.84%, 8.57% and 9.04% in 2008 to 39.14%, 14.20%, 12.17% and 12.30% in 2017 (table 1). As expected, a significant increase was confirmed for dyslipidaemia, diabetes and obesity in 2017 even standardised by age and sex (dyslipidaemia: 8.25% in 2008 and 11.95% in 2017, p<0.001; diabetes: 5.40% in 2008 and 6.68% in 2017, p<0.001; obesity: 7.44% in 2008 and 11.33% in 2017, p<0.001, table 1). Interestingly, we found that after standardisation for age and sex, the trend for hypertension was reversed with a slight decline in 2017 from 27.51% (26.53%–28.49%) to 25.16% (24.28%–26.04%).

When subjects were stratified by age, a constant downward trend of hypertension was identified among subjects younger than 70 years from 2008 to 2017 (figure 1A). The prevalent rates for dyslipidaemia, diabetes and obesity were higher in 2017 in each age subgroup (figure 1B–D). Especially, the prevalence of obesity in younger groups in 2017 dramatically increased as compared with that in 2008 (figure 1D). In contrast, the overall prevalence for the four signatures was similar when stratified by gender (figure 2A,B) or for patients identified by examination or self-reported alone (online supplementary table 3).

Changes in the four signatures stratified by gender among the different age groups were further analysed and presented in figure 3. It shows that the prevalence for male or female populations was similar in 2008 and 2017, respectively, for all but dyslipidaemia and obesity (figure 3). Similar results were seen for patients identified by examination or self-report alone (online supplementary table 4).

The distribution and numbers of cardiometabolic risk factors for 2008 and 2017 are shown in table 2. We found that 47.46%, 15.14% and 3.32% of the subjects had at least one, two and three, respectively, risk factors in 2008. In contrast, there was a gain in the percentage of risk factors in 2017 with 54.00%, 19.70% and 3.75%, respectively. The average numbers of cardiometabolic risk factors in 2008 and 2017 were 0.66 and 0.78 (p<0.001), respectively. And the numbers of cardiometabolic risk factors significantly increased with age (online supplementary figure 1).

**DISCUSSIONS**

To our knowledge, only a few previous studies have estimated cardiometabolic risk factors and future CVD burden in China before 2010.28,29 In the present study, we examined the prevalence of hypertension, dyslipidaemia and diabetes and the potential impact by a 10-year lag in Nanjing, China, in office-working populations.

In the past 10 years, the percentage of overweight and obesity showed an upward trend, which is consistent with the results from the 2010 China Chronic Disease Monitoring Programme.30 The worldwide ranking of obese populations of China has moved to the second position in 2014.31 During the last decades, the Chinese population have become more sedentary, especially for the working staff or retiree in the agency.32

Hypertension was reported to the most prominent cardiometabolic risk factors among the Chinese.33,34 From 1988 to 2008, there was an increasing trend of prevalence of hypertension in Americans aged 40 years and older,35 however, the prevalence of hypertension in Japan,36 Germany,37 Italy38 and Korea39 decreased. In our study,

![Figure 1](image1.png)  
**Figure 1** Age-specific prevalence of (A) hypertension, (B) dyslipidaemia, (C) diabetes and (D) obesity in 2008 and 2017.

![Figure 2](image2.png)  
**Figure 2** The age-standardised prevalence rates of the three cardiovascular disease factors in men (A) and women (B) in 2008 and 2017.

![Figure 3](image3.png)  
**Figure 3** Age-specific prevalence of (A) hypertension, (B) dyslipidaemia, (C) diabetes and (D) obesity among men and women in 2008 and 2017.
we found a significant decline in the prevalence trend for hypertension among Chinese adults in 2017 compared with 2008. As we all know, higher socioeconomic status could positively improve the awareness and control of hypertension, and people would also have better compliance to medical treatment. According to a survey in 13 provinces from 2009 to 2010, among 50 171 subjects aged at least 18 years, the awareness, treatment and control rates as well as the treatment control rate of hypertension were 42.6%, 34.1%, 9.3% and 27.4%, respectively, higher than those in 2002 (30.2%, 24.7%, 6.1% and 25.0%, respectively). 40

High blood LDL-C was the second leading risk factor for CVD. In agreement with previous Swiss, 41 French 42 and German 43 studies, the prevalence of hypercholesterolaemia increased significantly between 2008 and 2017. Diabetes is a growing epidemic in China, occurring at a relatively young age. 44 In the 1980s, diabetes was rare in China, with an estimated prevalence of 0.67%. In subsequent national surveys conducted in 1994, 45 2000–2001, 46 2007–2008 47 and 2010–2011, 48 the prevalence was 2.5%, 5.5%, 9.7% and 11.6%, respectively. In this study, we found that the crude prevalence increased from 8.5% in 2008 to 12.17% in 2017. These data imply that CVD events associated with high LDL and glucose will continue to increase in the future.

The main strength of this study was the use of two independent large health check-up populations with a sample size of approximately 10 000. All measurements and data were collected using standardised methods over time. Second, the exposure distribution of all risk factors was estimated on the basis of original data. The original data-based estimation allowed us to account for potential residual confounding, although it could not be completely eliminated.

The findings in the present study are subject to several limitations. First, we only considered four factors (blood pressure, LDL, glucose and BMI), without considering any dietary factors and smoking, because of the lack of data on these parameters. Second, this study was carried out in cohorts only comprising Chinese individuals from office-working units in Nanjing. Our results may not be generalisable to the entire population. More studies are expected to confirm our finding.

In conclusion, high blood pressure remains the leading factor among cardiometabolic risk factors in China, although a slight downward trend of this condition was observed from 2008 to 2017 after standardisation by age and sex. However, significant increases in dyslipidaemia, diabetes and obesity in 2017 were confirmed in the present study. More intensive screening and treatment regimens are needed for patients with these conditions, in order to curb the cardiovascular end points expected in the near future.

### Table 2 Details of cardiometabolic risk factors among Chinese subjects, who underwent check-up, in 2008 and 2017

| Cardiometabolic risk factors | 2008 (8017) | 2017 (9379) | P values |
|-----------------------------|------------|------------|---------|
| Obesity                     |            |            |         |
| Body mass index ≥28 kg/m²   | 725        | 1154       | <0.001  |
| Hypertension                | 3036       | 3671       | 0.09    |
| Dyslipidaemia               | 869        | 1332       | <0.001  |
| Diabetes                    | 687        | 1141       | <0.001  |
| ≥1 risk factor              | 3805       | 5065       | <0.001  |
| ≥2 risk factors             | 1214       | 1848       | <0.001  |
| ≥3 risk factors             | 266        | 352        | 0.13    |

### Acknowledgements
The authors thank all participants, researchers and support staff who have contributed to this study.

### Contributors
YC completed the analyses and led the writing. ZX-S and LB-G initiated, conceived and supervised the study. CS guided the analysis and modified the article. HL-Y assisted with the study and analyses. HZ participated in the data collection. XH-L and GY managed the physical examination. LK-Z and HD-Y checked the results of physical examination.

### Funding
This research was supported by grants 71373132 from National Natural Science Foundation of China, BK20151591 from National Science Foundation of Jiangsu, and 201605063 from the Nanjing Science and Technology Development Project.

### Competing interests
None declared.

### Patient consent for publication
Obtained.

### Ethics approval
The study was approved by the ethics committee of the Geriatric Hospital of Nanjing Medical University.

### Provenance and peer review
Not commissioned; externally peer reviewed.

### Data sharing statement
All available data are included in this manuscript.

### Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

### REFERENCES
1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006;3:e442.
2. Murray CJ, Barber RM, Foreman KJ, et al. GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 369 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 2015;386:2145–90.

3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.

4. Ahmad T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes mellitus on ischaemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422–6.

5. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 51 prospective studies. Lancet 2002;360:1903–13.

6. Eckel RH, York DA, Rössner S, et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004;110:29–75.

7. Bogers RP, Delemarre-Van de Waal H, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007;167:1720–8.

8. Prescott E, Hippe M, Schnohr P, et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998;316:1043–7.

9. Zimet PZ, Alberti KG. Introduction: Globalization and the non-communicable epidemic. Obesity 2006;14:1–13.

10. Maire B, Lloret S, Gartner A, et al. [Nutritional transition and non-communicable diet-related chronic diseases in developing countries]. Santé 2002;12:45–55.

11. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31–40.

12. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010;303:2043–50.

13. Hata J, Nominuma T, Hirakawa Y, et al. Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961–2008). Circulation 2013;128:1198–205.

14. Neuhouser HK, Adler C, Rosario AS, et al. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008–11. J Hum Hypertens 2015;29:247–53.

15. Di Loro A, Capparelli C, Palmieri L, et al. Time Trends of High Blood Pressure Prevalence, Awareness and Control in the Italian General Population: Surveys of the National Institute of Health. High Blood Press Cardiovasc Prev 2017;24:193–200.

16. Kim JH, Kim Y, Cho C, et al. The prevalence of major cardiovascular disease risk factors among Korean adults: results from the Korea National Health and Nutrition Examination Survey, 1998–2012. Int J Cardiol 2014;174:64–72.

17. Yuan Z, Zou Z, Zeng L, et al. Prevalence of diabetes and its risk factors, and pathophysiology. J Int J Cardiol 2007;12:45–55.

18. Zhang J, Zhang J, Zhang J, et al. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. J Hypertens 2015;33:177–88.

19. Zhou BF. Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults—study on optimal cut-off points of body mass index and waist circumference of diabetes. Clin Endocrinol 2002;57:153–96.

20. Vivanco-Hidalgo RM, Elosua R, Gómez González A, et al. People with epilepsy receive more statins than the general population but have no higher cardiovascular risk: results from a cross-sectional study. Eur J Neurol 2017;24:419–26.

21. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2008;185:327–91.

22. American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care 2015;38(Suppl S8):S1–S6.

23. Asci G, Marcelli D, Celtik A, et al. Comparison of Turkish and US haemodialysis patient mortality rates: an observational cohort study. Clin Nephrol 2016;85:77–80.

24. Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes 2010;3:24–52.

25. Li Y, Wang DD, Ley SH, et al. Potential Impact of Time Trend of Life-Style Factors on Cardiovascular Disease Burden in China. J Am Coll Cardiol 2016;68:818–33.

26. Weiwei C, Runlin G, Lisheng L, et al. Outline of the report on cardiovascular diseases in China, 2014. Eur Heart J Suppl 2016;18:F2–F11.

27. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 2016;388:1377–96.

28. Ng SW, Howard AG, Wang HJ, et al. The physical activity transition among adults in China: 1991–2011. Obes Rev 2014;15(Suppl 1):S7–36.

29. Yao C, Wu Z, Wu Y. The changing pattern of cardiovascular diseases in China. World Health Stat Q 2005;58:113–8.

30. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104:2855–64.

31. Egan SM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010;303:2043–50.

32. Hata J, Nominuma T, Hirakawa Y, et al. Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961–2008). Circulation 2013;128:1198–205.

33. Neuhouser HK, Adler C, Rosario AS, et al. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008–11. J Hum Hypertens 2015;29:247–53.

34. Di Loro A, Capparelli C, Palmieri L, et al. Time Trends of High Blood Pressure Prevalence, Awareness and Control in the Italian General Population: Surveys of the National Institute of Health. High Blood Press Cardiovasc Prev 2017;24:193–200.

35. Kim JH, Kim Y, Cho C, et al. The prevalence of major cardiovascular disease risk factors among Korean adults: results from the Korea National Health and Nutrition Examination Survey, 1998–2012. Int J Cardiol 2014;174:64–72.

36. Wang J, Zhang L, Wang F, et al. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens 2014;27:1355–61.

37. Galobardes B, Costanza MC, Bernstein MS, et al. Trends in risk factors for the major "lifestyle-related diseases" in Geneva, Switzerland, 1993–2000. Ann Epidemiol 2003;13:537–40.

38. Marques-Vidal P, Ruidavets JB, Amouyel P, et al. Change in cardiovascular risk factors in France, 1985–1995. Eur Heart J 1997;18:2644–50.

39. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104:2855–64.

40. Egan SM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010;303:2043–50.

41. Hata J, Nominuma T, Hirakawa Y, et al. Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961–2008). Circulation 2013;128:1198–205.

42. Neuhouser HK, Adler C, Rosario AS, et al. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008–11. J Hum Hypertens 2015;29:247–53.

43. Di Loro A, Capparelli C, Palmieri L, et al. Time Trends of High Blood Pressure Prevalence, Awareness and Control in the Italian General Population: Surveys of the National Institute of Health. High Blood Press Cardiovasc Prev 2017;24:193–200.